3/26
08:55 pm
ibrx
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
Low
Report
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
3/26
08:10 pm
ibrx
Investor Notice: Robbins LLP Informs Investors of the ImmunityBio, Inc. Class Action Lawsuit
Low
Report
Investor Notice: Robbins LLP Informs Investors of the ImmunityBio, Inc. Class Action Lawsuit
3/26
08:02 pm
ibrx
IBRX INVESTOR ALERT: ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit – RGRD Law
Low
Report
IBRX INVESTOR ALERT: ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit – RGRD Law
3/26
06:45 pm
ibrx
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of ImmunityBio, Inc. Investors – IBRX
Low
Report
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of ImmunityBio, Inc. Investors – IBRX
3/26
10:00 am
ibrx
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
High
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
3/26
09:31 am
ibrx
FDA Warning Puts ImmunityBio Anktiva Hopes And Valuation In Focus [Yahoo! Finance]
Low
Report
FDA Warning Puts ImmunityBio Anktiva Hopes And Valuation In Focus [Yahoo! Finance]
3/26
08:13 am
ibrx
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026 [Yahoo! Finance]
Medium
Report
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026 [Yahoo! Finance]
3/26
07:30 am
ibrx
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026
Medium
Report
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026
3/25
05:26 am
ibrx
FDA warns manufacturer that billionaire's claims about cancer drug Anktiva are misleading [CBS News]
Medium
Report
FDA warns manufacturer that billionaire's claims about cancer drug Anktiva are misleading [CBS News]
3/24
09:00 pm
ibrx
Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire About Securities Class Action Investigation – IBRX
Medium
Report
Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire About Securities Class Action Investigation – IBRX
3/24
02:11 pm
ibrx
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong [Yahoo! Finance Canada]
Medium
Report
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong [Yahoo! Finance Canada]
3/24
02:08 pm
ibrx
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong [Yahoo! Finance]
Medium
Report
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong [Yahoo! Finance]
3/24
01:02 pm
ibrx
Why ImmunityBio Stock Is Down More Than 20% Today [Yahoo! Finance]
Low
Report
Why ImmunityBio Stock Is Down More Than 20% Today [Yahoo! Finance]
3/24
11:11 am
ibrx
ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad [Yahoo! Finance]
Low
Report
ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad [Yahoo! Finance]
3/24
06:31 am
ibrx
A Look At ImmunityBio (IBRX) Valuation After ANKTIVA's Macau Approval And NCCN Guideline Expansion [Yahoo! Finance]
High
Report
A Look At ImmunityBio (IBRX) Valuation After ANKTIVA's Macau Approval And NCCN Guideline Expansion [Yahoo! Finance]
3/24
12:44 am
ibrx
ImmunityBio (IBRX) Soars 11% as Asian Expansion Looms [Yahoo! Finance]
High
Report
ImmunityBio (IBRX) Soars 11% as Asian Expansion Looms [Yahoo! Finance]
3/23
03:49 pm
ibrx
Why ImmunityBio Stock Is Up More Than 11% Today [Yahoo! Finance]
Low
Report
Why ImmunityBio Stock Is Up More Than 11% Today [Yahoo! Finance]
3/23
02:25 pm
ibrx
ImmunityBio (IBRX) Announces NCCN Update Clinical Practice Guidelines to Include ANKTIVA for Papillary-Only NMIBC [Yahoo! Finance]
Low
Report
ImmunityBio (IBRX) Announces NCCN Update Clinical Practice Guidelines to Include ANKTIVA for Papillary-Only NMIBC [Yahoo! Finance]
3/23
12:07 pm
ibrx
Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX? [Yahoo! Finance]
Medium
Report
Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX? [Yahoo! Finance]
3/23
10:52 am
ibrx
ImmunityBio (IBRX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $23.00 price target on the stock.
Low
Report
ImmunityBio (IBRX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $23.00 price target on the stock.
3/21
08:48 pm
ibrx
How Investors May Respond To ImmunityBio (IBRX) Securing First Asian Approval For ANKTIVA Via Macau Pathway [Yahoo! Finance]
Medium
Report
How Investors May Respond To ImmunityBio (IBRX) Securing First Asian Approval For ANKTIVA Via Macau Pathway [Yahoo! Finance]
3/21
08:18 pm
ibrx
Jim Cramer on ImmunityBio: “That Stock Is Part of the Magical Thinking Era” [Yahoo! Finance]
Medium
Report
Jim Cramer on ImmunityBio: “That Stock Is Part of the Magical Thinking Era” [Yahoo! Finance]
3/20
09:52 pm
ibrx
BTIG Sees Upside in ImmunityBio, Inc. (IBRX), Cites Strong 2026 ANKTIVA Sales Growth [Yahoo! Finance]
Medium
Report
BTIG Sees Upside in ImmunityBio, Inc. (IBRX), Cites Strong 2026 ANKTIVA Sales Growth [Yahoo! Finance]
3/20
01:08 pm
ibrx
ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
Low
Report
ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
3/19
07:27 pm
ibrx
Lightning Round: I can't recommend Stellantis, says Jim Cramer [CNBC]
Medium
Report
Lightning Round: I can't recommend Stellantis, says Jim Cramer [CNBC]